Oxford BioMedica reshuffles board
This article was originally published in Scrip
Oxford BioMedica has named Drs Paul Blake and Andrew Heath independent non-executive directors following the retirement of Mark Berninger from the board. Dr Blake is senior vice-president and chief medical officer of Aeterna Zentaris, while Dr Heath was CEO of Protherics from 1997 to 2008. Mr Berninger will step down from Oxford BioMedica, having served as an independent non-executive director since 1999. Separately, the firm has appointed Adam Love senior director of commercial activities and strategic planning; he was previously medical director for Cephalon and Archimedes.